NASDAQ:NXTC NextCure (NXTC) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free NXTC Stock Alerts $2.23 +0.29 (+14.95%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.82▼$2.2850-Day Range$1.13▼$2.2352-Week Range$0.98▼$2.28Volume1.02 million shsAverage Volume254,669 shsMarket Capitalization$62.22 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get NextCure alerts: Email Address NextCure MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside169.1% Upside$6.00 Price TargetShort InterestHealthy3.98% of Float Sold ShortDividend StrengthN/ASustainability-0.89Upright™ Environmental ScoreNews Sentiment0.29Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.80) to ($1.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.55 out of 5 starsMedical Sector102nd out of 938 stocksBiotechnology Industry1st out of 34 stocks 3.5 Analyst's Opinion Consensus RatingNextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, NextCure has a forecasted upside of 169.1% from its current price of $2.23.Amount of Analyst CoverageNextCure has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.98% of the float of NextCure has been sold short.Short Interest Ratio / Days to CoverNextCure has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NextCure has recently increased by 579.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNextCure does not currently pay a dividend.Dividend GrowthNextCure does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNextCure has received a 67.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for NextCure is -0.89. Previous Next 2.9 News and Social Media Coverage News SentimentNextCure has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for NextCure this week, compared to 0 articles on an average week.Search Interest9 people have searched for NXTC on MarketBeat in the last 30 days. MarketBeat Follows4 people have added NextCure to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NextCure insiders have not sold or bought any company stock.Percentage Held by Insiders11.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NextCure are expected to grow in the coming year, from ($1.80) to ($1.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NextCure is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NextCure is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNextCure has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About NextCure Stock (NASDAQ:NXTC)NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.Read More NXTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NXTC Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?March 23, 2024 | investorplace.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 23, 2024 | americanbankingnews.comNextCure (NASDAQ:NXTC) Given New $8.00 Price Target at HC WainwrightMarch 22, 2024 | markets.businessinsider.comPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy RatingMarch 22, 2024 | americanbankingnews.comNextCure (NASDAQ:NXTC) Rating Reiterated by Needham & Company LLCMarch 21, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)March 21, 2024 | marketwatch.comNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug CandidatesMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 21, 2024 | bizjournals.comMd. biopharma lays off staff, pauses manufacturing to preserve cashMarch 21, 2024 | globenewswire.comNextCure Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science AdvancesJanuary 18, 2024 | finance.yahoo.comNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway DisordersDecember 28, 2023 | benzinga.comNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and DatesDecember 25, 2023 | finance.yahoo.comHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom FishingDecember 21, 2023 | finance.yahoo.comNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord InjuryDecember 15, 2023 | finance.yahoo.comNextCure (NXTC) Down on Shelving Plans to Develop CandidateDecember 15, 2023 | markets.businessinsider.comBuy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline ShiftDecember 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)December 14, 2023 | msn.comNextCure stock falls 20% amid program shutdown, business updateDecember 14, 2023 | marketwatch.comNextCure Shares Fall 26% After Halting Development of One Drug CandidateDecember 14, 2023 | finance.yahoo.comNextCure Provides Year-End Clinical Pipeline UpdatesNovember 20, 2023 | finance.yahoo.comNextCure to Present at the 35th Annual Piper Sandler Healthcare ConferenceNovember 15, 2023 | finance.yahoo.comNextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLNovember 12, 2023 | morningstar.comNextCure Inc NXTCNovember 7, 2023 | msn.comAll You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to BuyNovember 2, 2023 | finance.yahoo.comNextCure Provides Business Update and Reports Third Quarter 2023 Financial ResultsSee More Headlines Receive NXTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:NXTC CUSIPN/A CIK1661059 Webwww.nextcure.com Phone(240) 399-4900FaxN/AEmployees82Year Founded2015Price Target and Rating Average Stock Price Target$6.00 High Stock Price Target$8.00 Low Stock Price Target$4.00 Potential Upside/Downside+169.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,720,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-47.03% Return on Assets-42.59% Debt Debt-to-Equity RatioN/A Current Ratio16.38 Quick Ratio16.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book0.54Miscellaneous Outstanding Shares27,900,000Free Float24,583,000Market Cap$62.22 million OptionableOptionable Beta0.37 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Michael S. Richman MSBA (Age 63)Co-Founder, CEO, President & Director Comp: $713.95kDr. Solomon Langermann Ph.D. (Age 64)Chief Scientific Officer Comp: $538.62kDr. Han Myint FACP (Age 71)M.D., Chief Medical Officer Comp: $554.46kDr. Lieping Chen M.D. (Age 66)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Mr. Steven P. Cobourn CPA (Age 61)Chief Financial Officer Comp: $313.25kDr. Timothy Mayer Ph.D. (Age 59)Chief Operating Officer Mr. Kevin G. Shaw (Age 50)General Counsel Ms. Stacy RollingerVice President of Human ResourcesMr. Sourav Kundu Ph.D. (Age 64)Senior Vice President of Development & Manufacturing Dr. Sebastien MalovesteSenior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsReneo PharmaceuticalsNASDAQ:RPHMCleneNASDAQ:CLNNRallybioNASDAQ:RLYBHomology MedicinesNASDAQ:FIXXAadi BioscienceNASDAQ:AADIView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 26,550 shares on 2/26/2024Ownership: 0.095%Cable Car Capital LLCBought 615,878 shares on 2/20/2024Ownership: 2.207%ADAR1 Capital Management LLCBought 60,414 shares on 2/14/2024Ownership: 0.217%Northern Trust CorpSold 10,010 shares on 2/13/2024Ownership: 0.118%Dimensional Fund Advisors LPSold 9,867 shares on 2/7/2024Ownership: 0.308%View All Institutional Transactions NXTC Stock Analysis - Frequently Asked Questions Should I buy or sell NextCure stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares. View NXTC analyst ratings or view top-rated stocks. What is NextCure's stock price target for 2024? 2 analysts have issued 1-year price objectives for NextCure's stock. Their NXTC share price targets range from $4.00 to $8.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 169.1% from the stock's current price. View analysts price targets for NXTC or view top-rated stocks among Wall Street analysts. How have NXTC shares performed in 2024? NextCure's stock was trading at $1.14 at the start of the year. Since then, NXTC stock has increased by 95.6% and is now trading at $2.23. View the best growth stocks for 2024 here. Are investors shorting NextCure? NextCure saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 839,700 shares, an increase of 579.9% from the February 29th total of 123,500 shares. Based on an average trading volume of 229,500 shares, the short-interest ratio is presently 3.7 days. Approximately 4.0% of the company's shares are sold short. View NextCure's Short Interest. When is NextCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NXTC earnings forecast. How were NextCure's earnings last quarter? NextCure, Inc. (NASDAQ:NXTC) announced its earnings results on Thursday, November, 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.02. What other stocks do shareholders of NextCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), Organigram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT). When did NextCure IPO? NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO. Who are NextCure's major shareholders? NextCure's stock is owned by many different institutional and retail investors. Top institutional investors include Cable Car Capital LLC (2.21%), Acuitas Investments LLC (1.34%), Federated Hermes Inc. (1.18%), Dimensional Fund Advisors LP (0.31%), ADAR1 Capital Management LLC (0.22%) and Marquette Asset Management LLC (0.21%). View institutional ownership trends. How do I buy shares of NextCure? Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NXTC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.